---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-006784"
form_type: "8-K"
ticker: "ACON"
cik: "0001635077"
company_name: "Aclarion, Inc."
filed_at: "2023-09-28T23:59:59+00:00"
generated_at: "2026-06-10T07:39:03.686531+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "medium"
source: SEC EDGAR
---

# Aclarion updates investor deck; highlights CLARITY trial start Q4 2023 with 300 patients

## Summary
- CLARITY prospective randomized trial begins Q4 2023; 300 patients, 42-month timeline, Johns Hopkins anchor site.
- NIH BACPAC studies (comeBACK, BEST) using Nociscan; enrollment ongoing, expected completion Q2 2024.
- CPT Category III codes 0609T and 0611T secured Jan 2021; early commercialization in progress.
- 39 issued US/international patents plus 13 pending; market opportunity up to $135B low back pain market.

## SEC filing metadata
- accession: 0001683168-23-006784
- form_type: 8-K
- ticker: ACON
- cik: 0001635077
- company_name: Aclarion, Inc.
- filed_at: 2023-09-28T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635077/000168316823006784/0001683168-23-006784-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635077/000168316823006784/acon_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-006784
- JSON: https://secwatch.observer/filing/0001683168-23-006784.json
- Plain text: https://secwatch.observer/filing/0001683168-23-006784.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.